Loading…
Biotech holding company that creates and funds separate subsidiaries ('Vants') to develop and commercialize individual drugs.
Biotech holding company that creates and funds separate subsidiaries ('Vants') to develop and commercialize individual drugs.
Creates subsidiaries around single drugs and funds them from the parent, then makes money by selling or partnering them, as with the 2023 sale of Telavant to Roche, rather than from product sales. It holds a majority of the listed Immunovant, and of Genevant, which licenses a lipid-nanoparticle delivery technology and is in patent disputes with vaccine makers.
Moat: none (process know-how). Repeatable in-licensing/spin-out playbook, but no single therapeutic moat; success rides on individual pipeline bets.
Headquarters: New York, New York, United States · Founded: 2014 · Employees: 721
Size Roivant Sciences (ROIV) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $28.1B, the 385th largest of 3,117 United States companies the cockpit tracks. Shares closed at $38.88 on 6 Nov 2026.
Performance Over six months the shares gained 36.1%, against +9.8% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue fell 67.6% over the last twelve months (peer median +16.7%); the operating margin is -18,146.1% (peer median 18.6%).
Valuation It trades at 3,323.9× enterprise value to sales against a peer median of 4.4× (most expensive of 21).
Capital Return on invested capital runs 68.6 points below its cost of capital (11.0% WACC).
Short interest Short interest is 5.6% of the free float (15 Oct 2026).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $7.53M | $8.26M | $29.1M | $32.7M | $61.3M |
| Revenue growth | — | -72% | -11% | -47% | — |
| Gross profit | $3.27M | $3.63M | $20.8M | $20.5M | $29.2M |
| EBITDA | -$1.36B | -$1.26B | -$1.11B | -$814M | -$1.05B |
| Net income | -$266M | -$300M | -$172M | $4.35B | -$1.01B |
| Free cash flow | -$821M | -$759M | -$844M | -$767M | -$856M |
| Capital expenditure | $4.59M | $8.21M | $4.60M | $1.38M | $12.7M |
| Total debt | $107M | $107M | $100M | $54.0M | $487M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Roivant Sciences ROIV | $28.1B | +36% | -68% | -18,146% | 3,323.9× | n/a |
| Ligand Pharmaceuticals LGND | $6.12B | +38% | +1% | 14% | 26.9× | 57.8% |
| PureTech Health PRTC.L | $394M | -8% | -4% | -1,617% | 28.4× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ROIV | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.7% | +8.1% | 8th highest of 21 |
| 6-month return | +36.1% | +9.8% | 3rd highest of 21 |
| Distance from 52-week high | -8.5% | -10.0% | 8th highest of 21 |
| Revenue growth (TTM) | -67.6% | +16.7% | lowest of 21 |
| Operating margin | -18,146.1% | 18.6% | lowest of 21 |
| EV / Sales | 3,323.9× | 4.4× | most expensive of 21 |
| ROIC minus cost of capital | -68.6 pp | +5.5 pp | 2nd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Roivant Sciences ROIV | United States | $28.1B | +36% | -68% | -18,146% | 3,323.9× | n/a | n/a |
| Astellas Pharma 4503.T | Japan | $28.2B | +11% | +19% | 23% | 1.9× | -11.0% | +11.4% |
| Divi's Laboratories DIVISLAB.NS | India | $29.0B | +54% | +16% | 31% | 24.4× | 50.9% | +8.9% |
| Hansoh Pharma 3692.HK | Hong Kong | $26.9B | -7% | +25% | 38% | 9.7× | 8.9% | +10.8% |
| Insmed INSM | United States | $25.1B | -16% | +240% | -42% | 16.2× | n/a | n/a |
| Daiichi Sankyo 4568.T | Japan | $31.9B | +7% | +17% | 13% | 2.1× | 7.2% | +17.1% |
| Incyte INCY | United States | $24.4B | +21% | +25% | 12% | 3.4× | 14.2% | +14.0% |
| Zoetis ZTS | United States | $32.8B | -4% | +1% | 38% | 4.2× | -4.3% | +7.2% |
| Viatris VTRS | United States | $22.9B | +17% | +5% | 10% | 2.4× | 12.5% | +3.7% |
| Sigma Healthcare SIG.AX | Australia | $22.4B | -1% | +209% | 9% | 3.2× | 28.2% | +26.1% |
| Biogen BIIB | United States | $36.7B | +28% | +2% | 17% | 4.4× | 9.4% | -5.1% |
| Alnylam Pharmaceuticals ALNY | United States | $20.9B | -47% | +56% | 20% | 4.0× | 0.9% | +49.8% |
| Otsuka Hldgs 4578.T | Japan | $38.6B | +2% | +11% | 18% | 2.2× | 0.4% | +11.7% |
| Royalty Pharma RPRX | United States | $38.8B | +33% | +11% | 66% | 19.0× | 9.9% | +2.3% |
| Haleon HLN.L | United Kingdom | $40.1B | +1% | +1% | 23% | 3.3× | 4.6% | +2.2% |
| Innovent Biologics 1801.HK | Hong Kong | $19.2B | -5% | +43% | 17% | 7.4× | 11.7% | +26.8% |
| Torrent Pharmaceuticals TORNTPHARM.NS | India | $19.1B | +9% | +42% | 22% | 11.0× | 37.9% | +11.3% |
| Sandoz SDZ.SW | Switzerland | $44.4B | +24% | +1% | 15% | 4.4× | 7.9% | +0.4% |
| Swedish Orphan Biovitrum SOBI.ST | Sweden | $17.6B | +13% | +15% | 30% | 5.8× | -1.1% | +13.1% |
| BeOne Medicines 688235.SS | China | $45.8B | +19% | +28% | 15% | 6.8× | 23.3% | +79.3% |
| Exelixis EXEL | United States | $17.0B | +44% | +9% | 40% | 6.5× | -3.7% | +18.6% |